Miramoon Pharma 

First in Class Drugs for Neurodegenerative and Rare Diseases

OWNER

Pablo Ferrón (See Profile)


Sector

Therapeutics

Stage

Prototyping, preclinical

Country

España


UNIQUE TOPICAL ADMINISTRATION FOR THE TREATMENT OF RETINITIS PIGMENTOSA. NON GENE-MUTATION DEPENDENT TECHNOLOGY.

COMBINABLE WITH GENE THERAPY AND OTHER THERAPEUTIC APPROACHES. IMPROVES RODS AND CONES´ STRUCTURE AND FUNCTION.

LOW TOXICITY DUE TO SPECIFIC MECHANISM. EASILY SCALABLE SYNTHESIS AND LOW MANUFACTURE COST.

Status

Approved

IP Type

Patent

Time

16 years

Countries

Australia
Austria
Belgium
Canada
China
Denmark
Finland
France
Germany
Israel
Italy
Japan
Netherlands
Russia
Spain
Switzerland
USA
United Kingdom

Coverage

The invention relates to 1,2,3-triazoles of formula:useful for improving or restoring the intracellular calcium homeostasis and RyR-calstabin binding function in human and animal cells. The present invention also relates to methods for synthesizing said compounds, to pharmaceutical compositions containing them, and to the use thereof for preventing or treating skeletal muscle, heart and nervous system disorders.

Know more of this patent

Status

Pending

IP Type

Patent

Time

Countries

Australia
Austria
Belgium
Canada
China
Denmark
Finland
France
Germany
Israel
Italy
Japan
Netherlands
Russia
South Korea
Spain
Switzerland
USA
United Kingdom

Coverage

The present invention relates to substituted 1,2,3-triazoles useful for the treatment of
ocular diseases, in particular those related to retinal degeneration such as retinitis
pigmentosa. The invention also relates to a subgroup of new substituted 1,2,3-triazoles.

Know more of this patent

This information is confidential, do not share or copy.

Under evaluation at least till: 10th of February 2023

If you want to have more information or you want to review the project, you have to login or register

KEEP REVIEWING

©2023 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

ACEPTAR
Aviso de cookies

Log in with your credentials

or    

Forgot your details?

Create Account

Skip to toolbar